The abstract is read at the publisher; the summary is JClub's.
Concurrent ADT plus androgen receptor pathway inhibitor therapy in prostate cancer is linked to a steadily rising 12-month cumulative incidence of metabolic syndrome, nearing 40%, with age-specific peaks.
- Why it matters: Men receiving ADT-ARPI may develop cardiometabolic problems, but the timing and occurrence of metabolic syndrome during the first year—especially across ages—were not well defined.
- What they did: In a retrospective cohort of 16,924 men without baseline metabolic syndrome or components, investigators used Epic Cosmos records to track new-onset metabolic syndrome for up to 12 months after the first overlap date of ADT and ARPI.
- The result: Hypertension was the most frequently documented component, and metabolic syndrome incidence was highest at ages 70 to 79 years (51.7 events per 1000 person-months; 95% CI, 50.7-53.9), with exploratory differences by ARPI type.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.